natgillin/translations-raw huggingface dataset:
Pins and needles and numbness
Trnci i utrnulost
pins and needles sensation
trnci i bockanje
Pins and needles, feeling weak, numb, tingling or pain in the lower back or leg (sciatica); feeling numb, burning, tingling or pain in the hands and fingers (carpal tunnel syndrome)
trnci i bockanje, osjećaj slabosti, utrnulost, trnci ili bol u donjem dijelu leđa ili noge (išijas); osjećaj utrnulosti, žarenje, trnci ili bol u rukama i prstima (sindrom karpalnog tunela)
pins and needles, reduced sensation, taste changes discomfort in the mouth
osjećaj mravinjanja i bockanja, oslabljen osjet, promjene okusa neugodan osjećaj u ustima
pioglitazone (a particular class of medicines to treat diabetes) rifampicin (a medicine used to treat tuberculosis)
pioglitazon (posebna klasa lijekova za liječenje šećerne bolesti) rifampicin (lijek koji se koristi za liječenje tuberkuloze).
pioglitazone (a particular class of medicines to treat diabetes) rifampicin (a medicine used to treat tuberculosis).
pioglitazon (posebna klasa lijekova za liječenje šećerne bolesti) rifampicin (lijek koji se koristi za liječenje tuberkuloze).
pioglitazone (N=136)
+ pioglitazon (N=136)
Pioglitazone (tablets used for the treatment of type 2 diabetes)
Pioglitazon (tablete za liječenje šećerne bolesti tipa 2)
Pioglitazone + Metformin
Pioglitazon + metformin
Pioglitazone - oral anti-diabetic medicine used to treat type 2 diabetes mellitus.
Pioglitazon - lijek za liječenje šećerne bolesti tipa 2 koji se uzima kroz usta.
Pioglitazone Accord 15 mg tablets are white to off white, round, biconvex, uncoated tablets debossed with ‘P’ on one side and ‘15’ on other side.
Pioglitazone Accord 15 mg tablete su bijele do gotovo bijele boje, okrugle, bikonveksne, bez ovojnice i s utisnutom oznakom ‘P’ s jedne strane i ‘15’ s druge strane.
Pioglitazone Accord 15 mg tablets Pioglitazone Accord 30 mg tablets Pioglitazone Accord 45 mg tablets Pioglitazone
Pioglitazone Accord 15 mg tablete Pioglitazone Accord 30 mg tablete Pioglitazone Accord 45 mg tablete pioglitazon
Pioglitazone Accord 30 mg tablets are white to off white, flat, round uncoated tablets with beveled edges debossed with ‘PIO’ on one side and ‘30’ on the other side.
Pioglitazone Accord 30 mg tablete su bijele do gotovo bijele boje, okrugle, plosnate tablete bez ovojnice sa zaobljenim rubovima i utisnutom oznakom ‘PIO’ s jedne strane i ‘30’ s druge strane.
Pioglitazone Accord 45 mg tablets are white to off white, flat, round uncoated tablets with beveled edges debossed with ‘PIO’ on one side and ‘45’ on the other side.
Pioglitazone Accord 45 mg tablete su bijele do gotovo bijele boje, plosnate, okrugle tablete bez ovojnice sa zaobljenim rubovima i utisnutom oznakom ‘PIO’ s jedne strane i ‘45’ s druge strane.
Pioglitazone Accord contains lactose monohydrate
Pioglitazone Accord sadrži laktozu hidrat
Pioglitazone Accord is available in Aluminium/Aluminium blister packs containing 14, 28, 30, 50, 56, 84,
Pioglitazone Accord je dostupan u aluminij/aluminij blister pakiranjima s 14, 28, 30, 50, 56, 84, 90,
Pioglitazone Accord tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption.
Tablete Pioglitazone Accord sadrže laktozu hidrat te se stoga ne smiju primjenjivati u bolesnika s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcijom glukoze-galaktoze.
Pioglitazone Accord with food and drink
Pioglitazone Accord s hranom i pićem
Pioglitazone Actavis 15 mg
Pioglitazon Actavis 15 mg
Pioglitazone Actavis 15 mg tablets
Pioglitazon Actavis 15 mg tablete
Pioglitazone Actavis 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved with ‘TZ15’ on one side.
Pioglitazon Actavis 15 mg tablete su bijele, okrugle, ravne s ukošenim rubom, promjera 5,5 mm s utisnutom oznakom ‘TZ15’ na jednoj strani.
Pioglitazone Actavis 15 mg tablets Pioglitazone
Pioglitazon Actavis 15 mg tablete pioglitazon
Pioglitazone Actavis 30 mg
Pioglitazon Actavis 30 mg
Pioglitazone Actavis 30 mg tablets
Pioglitazon Actavis 30 mg tablete
Pioglitazone Actavis 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved with ‘TZ30’ on one side.
Pioglitazon Actavis 30 mg tablete su bijele, okrugle, ravne s ukošenim rubom, promjera 7 mm s utisnutom oznakom ‘TZ30’ na jednoj strani.
Pioglitazone Actavis 30 mg tablets Pioglitazone
Pioglitazon Actavis 30 mg tablete pioglitazon
Pioglitazone Actavis 45 mg
Pioglitazon Actavis 45 mg
Pioglitazone Actavis 45 mg tablets
Pioglitazon Actavis 45 mg tablete
Pioglitazone Actavis 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved with ‘TZ45’ on one side.
Pioglitazon Actavis 45 mg tablete su bijele, okrugle, ravne s ukošenim rubom, promjera 8 mm s utisnutom oznakom ‘TZ45’ na jednoj strani.
Pioglitazone Actavis 45 mg tablets Pioglitazone
Pioglitazon Actavis 45 mg tablete pioglitazon
Pioglitazone Actavis contains lactose monohydrate
Pioglitazon Actavis sadrži laktozu hidrat
Pioglitazone Actavis may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as insulin) which have failed to provide sufficient control in blood sugar.
Pioglitazon Actavis se može primjenjivati sam u bolesnika koji ne mogu uzimati metformin, a kod kojih se liječenjem dijetom i tjelovježbom nije uspjela postići kontrola šećera u krvi ili se može dodati drugim lijekovima (kao što je inzulin) koji nisu uspjeli osigurati dostatnu kontrolu šećera u krvi.
Pioglitazone Actavis may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as insulin) which have failed to provide sufficient control of blood sugar.
Pioglitazon Actavis se može primjenjivati sam u bolesnika koji ne mogu uzimati metformin, a kod kojih se liječenjem dijetom i tjelovježbom nije uspjela postići kontrola šećera u krvi ili se može dodati drugim lijekovima (kao što je inzulin) koji nisu uspjeli osigurati dostatnu kontrolu šećera u krvi.
Pioglitazone Actavis with food and drink
Pioglitazon Actavis s hranom i pićem
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).
Pioglitazon i svi djelatni metaboliti u velikom su opsegu vezani za proteine plazme (>99%).
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).
Pioglitazon i svi djelatni metaboliti uglavnom su vezani za proteine plazme (>99%)
Pioglitazone and all active metabolites are extensively bound to plasma protein (> 99%).
Pioglitazon i svi djelatni metaboliti uglavnom su vezani za proteine plazme (>99%).
Pioglitazone and all active metabolites are extensively bound to plasma protein (>99%).
Pioglitazon i svi djelatni metaboliti opsežno se vežu za proteine plazme (> 99%).
Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals.
Pioglitazon vjerojatno djeluje putem aktivacije posebnih receptora u jezgri (receptor gama aktiviran peroksizomskim proliferatorom – PPAR gama), što u životinja dovodi do povećane osjetljivosti jetre, masnog tkiva i skeletnih mišića na inzulin.
Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals.
Pioglitazon vjerojatno djeluje putem aktivacije posebnih receptora u jezgri (receptor gama aktiviran peroksizomskim proliferatorom – PPAR gama), što u životinja dovodi do povećane osjetljivosti jetre, masnog tkiva i skeletnih mišićnih stanica na inzulin.
Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus in adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4).
Pioglitazon je također indiciran u kombinaciji s inzulinom u odraslih bolesnika sa šećernom bolešću tipa 2 i nedostatnom kontrolom glikemije pomoću inzulina u kojih je metformin neprikladan zbog kontraindikacija ili nepodnošljivosti (vidjeti dio 4.4).
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:
Pioglitazon je indiciran kao druga ili treća linija liječenja šećerne bolesti tipa 2 na sljedeći način: kao monoterapija
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: as monotherapy
Pioglitazon je indiciran kao druga ili treća linija liječenja šećerne bolesti tipa 2 na sljedeći način: kao monoterapija
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus described below: as monotherapy
Pioglitazon je indiciran kao druga ili treća linija liječenja šećerne bolesti tipa 2 na sljedeći način: kao monoterapija
Pioglitazone Krka contains lactose monohydrate
Pioglitazone Krka sadrži laktozu hidrat
Pioglitazone Krka tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption.
Pioglitazone Krka tablete sadrže laktozu hidrat te se stoga ne smiju primjenjivati u bolesnika s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatka Lapp laktaze ili malapsorpcijom glukoze-galaktoze.
Pioglitazone Krka with food and drink
Pioglitazone Krka s hranom i pićem
Pioglitazone Teva 15 mg tablets are white to off white, round, convex with the number ‘15’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva 15 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘15’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva 15 mg tablets Pioglitazone Teva 30 mg tablets Pioglitazone Teva 45 mg tablets Pioglitazone
Pioglitazon Teva 15 mg tablete Pioglitazon Teva 30 mg tablete Pioglitazon Teva 45 mg tablete pioglitazon
Pioglitazone Teva 30 mg tablets are white to off white, round, convex with the number ‘30’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva 30 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘30’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva 45 mg tablets are white to off white, round, convex with the number ‘45’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva 45 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘45’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva Pharma 15 mg tablets are white to off white, round, convex with the number ‘15’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva Pharma 15 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘15’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva Pharma 15 mg tablets EU/1/12/758/001-010
Pioglitazon Teva Pharma 15 mg tablete EU/1/12/758/001-010
Pioglitazone Teva Pharma 15 mg tablets Pioglitazone
Pioglitazon Teva Pharma 15 mg tablete pioglitazon
Pioglitazone Teva Pharma 15 mg tablets Pioglitazone Teva Pharma 30 mg tablets Pioglitazone Teva Pharma 45 mg tablets
Pioglitazon Teva Pharma 15 mg tablete Pioglitazon Teva Pharma 30 mg tablete Pioglitazon Teva Pharma 45 mg tablete
Pioglitazone Teva Pharma 30 mg tablets
Pioglitazon Teva Pharma 45 mg tablete
Pioglitazone Teva Pharma 30 mg tablets are white to off white, round, convex with the number ‘30’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva Pharma 30 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘30’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva Pharma 30 mg tablets EU/1/12/758/011-020
Pioglitazon Teva Pharma 30 mg tablete
Pioglitazone Teva Pharma 30 mg tablets Pioglitazone
Pioglitazon Teva Pharma 30 mg tablete pioglitazon
Pioglitazone Teva Pharma 45 mg tablets are white to off white, round, convex with the number ‘45’ on one side and ‘TEVA’ on the other side.
Pioglitazon Teva Pharma 45 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘45’ na jednoj strani i ‘TEVA’ na drugoj.
Pioglitazone Teva Pharma 45 mg tablets Pioglitazone
Pioglitazon Teva Pharma 45 mg tablete pioglitazon
Pioglitazone Teva Pharma has no or negligible influence on the ability to drive and use machines.
Pioglitazon Teva Pharma ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Pioglitazone Teva Pharma should be used every day to work properly.
Da bi Pioglitazon Teva Pharma ispravno djelovao, treba ga uzimati svaki dan.
Pioglitazone Teva Pharma with food and drink
Pioglitazon Teva Pharma s hranom i pićem
Pioglitazone Teva with food and drink
Pioglitazon Teva s hranom i pićem
Pioglitazone used together with insulin, see ‘Pioglitazone’ below.
Uzimanje pioglitazona zajedno s inzulinom, vidjeti dolje ‘Pioglitazon’.
Pioglitazone – oral anti-diabetic medicine used to treat type 2 diabetes mellitus.
Pioglitazon - lijek za liječenje šećerne bolesti tipa 2 koji se uzima kroz usta.
Pioglitazone – tablets used for the treatment of type 2 diabetes mellitus.
Pioglitazon – tablete koje se koriste za liječenje šećerne bolesti tipa 2.
pioglitazone, rosiglitazone, repaglinide, tolbutamide and glipizide (used to treat diabetes),
pioglitazon, roziglitazon, repaglinid, tolbutamid i glizipid (koriste se za liječenje šećerne bolesti),
Piperaquine has an absorption maximum at 352 nm.
Maksimum apsorpcije piperakina je na 352 nm.
Piperaquine is a bisquinoline, and this class has shown good antimalarial activity against chloroquine- resistant Plasmodium strains in vitro.
Piperakin je biskinolin, a ta je skupina pokazala dobro antimalarijsko djelovanje protiv sojeva Plasmodium rezistentnih na klorokin in vitro.
Piperaquine is metabolised by CYP3A4 in vitro.
CYP3A4 metabolizira piperakin in vitro.
Piperaquine is metabolised by, and is an inhibitor of CYP3A4.
Piperakin je inhibitor CYP3A4, koji ga i metabolizira.
Piperaquine tetraphosphate/artenimol
piperakintetrafosfat/artenimol
PIPETTE
PIPETE
Pipette (plastic/Alu
Pipeta (plastika/Al u/plastika)
Pipette (PP/Alu/PP)
Pipete (PP/Alu/PP)
Pipette 137.5 mg
Pipeta (137,5 mg)
Pipette 275 mg
Pipeta (275 mg)
Pipette 56.25 mg
Pipeta (56,25 mg)
Pipette 625 mg
Pipeta (625 mg)
Pipette cap colour
Boja zatvarača pipete
Pipette composed of high density polyethylene (body and cannula) containing a steel ball.
Pipeta od polietilena visoke gustoće ( tijelo i kanila ) koja sadržava čeličnu kuglicu.
PIPETTE LABEL
OZNAČAVANJE PIPETA
Pipette size to be used
Veličina pipeta za korištenje
Pipette size to be used
Veličina pipete
Pipette size to be used
Veličina pipete koja se koristi
Pipette size to be used
Veličina pipete koja se primjenjuje
Pirfenidone is not considered to present a potential risk to surface water, microorganisms and ground water or to sediment-dwelling invertebrates.
Ne smatra se da pirfenidon predstavlja potencijalan rizik za površinske vode, mikroorganizme, podzemne vode ni beskralježnjake koji obitavaju u tlu.
Pirlimycin has been shown to accumulate in polymorphonuclear cells, however, intracellular killing of Staphylococcus aureus was not demonstrated.
Dokazano je da se pirlimicin akumulira u polimorfonuklearnim stanicama, međutim, unutar stanično ubijanje zlatnog stafilokoka nije dokazano.
Pirlimycin hydrochloride equivalent to 50 mg pirlimycin per 10 ml syringe
Pirlimicin hidroklorid ekvivalentan količini od 50 mg pirlimicina po štrcaljki od 10 ml
Pirlimycin hydrochloride equivalent to 50 mg pirlimycin per 10 ml syringe For the full list of excipients see Section 6.1
Pirlimicin hidroklorid ekvivalentan količini od 50 mg pirlimicina po štrcaljki od 10 ml Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
piroxicam - used for arthritis
piroksikam - koristi se za artritis
PIRSUE 5 mg/ml intramammary solution for cattle
PIRSUE 5 mg/ml intramamarna otopina za goveda
PIs or NNRTIs is unlikely.
IP-a ili NNRTI-ja.
PIs or NNRTIs is unlikely.
PI ili NNRTI nije vjerojatna.
PIs or NNRTIs is unlikely.
PI ili NNRTI) nije vjerojatna.
PIs or NNRTIs) is unlikely.
IP ili NNRTI) nije vjerojatna.
pite of this, a small increase in cortisol suppression was seen after administration of fixed-dose combination compared to the monoproducts.
Usprkos tome, primijećeno je malo povećanje supresije kortizola nakon primjene kombinacije fiksne doze u usporedbi s monokomponentama.
Pitolisant has a plasma half-life of 10-12 hours.
Pitolizantov poluvijek u plazmi je 10 – 12 sati.
Pitolisant is contra-indicated in patients with severe hepatic impairment (Child-Pugh C) (see section 4.3).
Pitolizant je kontraindiciran u bolesnika s teškim oštećenjem jetre (Child-Pugh C) (vidjeti dio 4.3).
Pitolisant shows greater than 50% inhibition towards OCT1 (organic cation transporters 1) at 1.33 µM, the extrapolated IC50 of pitolisant is 0.795 µM (see section 4.5).
Pitolizant pokazuje inhibiciju veću od 50 % prema OCT1 (prijenosnik organskih kationa 1) pri 1,33 µM, ekstrapolirani IC50 pitolizanta je 0,795 µM (vidjeti dio 4.5).
Pitting oedema
Tjestasti edemi
Pitting oedema*
tjestasti edem
pitting of blood or nosebleed
iskašljavanje krvi ili krvarenje iz nosa
Pituitary function and hormone levels should be monitored to ensure appropriate hormone replacement.
Potrebno je nadzirati funkciju hipofize i vrijednosti hormona kako bi se osigurao odgovarajući nadomjestak hormona.
pituitary gland not working properly – this may cause low blood levels of some hormones that affect the function of the male or female sex organs hearing problems
neispravan rad hipofize – to može uzrokovati niske razine nekih hormona koji utječu na funkciju muških odnosno ženskih spolnih organa tegobe sa sluhom
pituitary gland not working properly – this may cause low blood levels of some hormones that affect the function of the male or female sex organs hearing problems
neispravan rad hipofize – to može uzrokovati niske razine nekih hormona koji utječu na funkciju muških odnosno ženskih spolnih organa tegobe sa sluhom.
pituitary gland not working properly – this may cause low blood levels of some hormones that affect the function of the male or female sex organs hearing problems
neispravan rad hipofize – to može uzrokovati niske razine nekih hormona koji utječu na funkciju muških odnosno ženskih spolnih organa, tegobe sa sluhom.
Pivotal Studies MS-F203 and MS-F204
Ključna ispitivanja MS-F203 i MS-F204
Pivotal study (07-AVR-123)
Glavno ispitivanje (07-AVR-123)
Pivotal Study (N= 25) ZLB03_002CR
Pivotalno ispitivanje (N = 25) ZLB03_002CR
Pivotal study of Cerdelga in GD1 patients switching from ERT– Study 02607 (ENCORE)
Pivotalno ispitivanje lijeka Cerdelga u bolesnika s GD1 koji su prešli s ERT-a - ispitivanje 02607 (ENCORE)
Pivotal study of Cerdelga in treatment-naïve GD1 patients – study 02507(ENGAGE)
Pivotalno ispitivanje lijeka Cerdelga u prethodno neliječenih bolesnika s GD1 - ispitivanje 02507 (ENGAGE)
Pivotal Study – Study 209 (Core Phase; ITT)
Glavno ispitivanje – Ispitivanje 209 (središnja faza; ITT)
Pivotal trials for Prevenar 13 were designed to show that functional OPA antibody responses for the 13 serotypes are non-inferior, and for some serotypes superior, to the 12 serotypes in common with the licensed 23-valent pneumococcal polysaccharide vaccine [1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] one month after vaccine administration.
Ključna ispitivanja Prevenara 13 bila su ustrojena tako da pokažu neinferiornost odgovora funkcionalnih OPA protutijela na 13 serotipova i njihovu superiornost za neke serotipove u odnosu na 12 zajedničkih serotipova u odobrenom 23-valentnom pneumokoknom polisaharidnom cjepivu [1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F] mjesec dana nakon primjene cjepiva.
PIX 301 Overall survival–end of study
PIX 301 – Ukupno preživljenje – na kraju ispitivanja
Pixantrone
Piksantron
Pixantrone dimaleate up to 27 mg/kg given twice a week for 4 weeks did not induce any cardiotoxic effects, while mitoxantrone, as expected, was cardiotoxic at all tested doses (0.6, 1.6, and 1.5 mg/kg).
Piksantrondimaleat, u dozi do 27 mg/kg dva puta tjedno kroz 4 tjedna nije inducirao kardiotoksične učinke, dok je mitoksantron, prema očekivanju, bio kardiotoksičan u svim ispitivanim dozama (0,6, 1,6, i 1,5 mg/kg).
Pixantrone has a moderate to high total plasma clearance of 72.7 l/hr and a low renal excretion accounting for less than 10% of the administered dose in 0-24 hours.
Ukupni plazma klirens piksantrona je umjeren do velik i iznosi 72,7 l/h, a izlučivanje putem bubrega je manje od 10% primijenjene doze unutar 0-24 sata.
Pixantrone may induce hyperuricaemia as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of neoplastic cells (tumour lysis syndrome) and can lead to electrolyte imbalances, which can result in kidney damage.
Piksantron može inducirati nastanak hiperuricemije kao posljedicu jakog katabolizma purina koji prati brzu lizu tumorskih stanica (sindrom lize tumora) izazvanu lijekovima i može dovesti do disbalansa elektrolita, koji pak može uzrokovati oštećenje bubrega.
Pixantrone was a poor inhibitor of OATP1B1 and OATP1B3 uptake transporters in vitro.
In vitro pixantrone je bio slab inhibitor preuzimanja transportera OATP1B1 i OATP1B3.
Pixuvri 29 mg powder for concentrate for solution for infusion
Pixuvri 29 mg prašak za koncentrat za otopinu za infuziju
Pixuvri belongs to a pharmacotherapeutic group of medicines known as ‘antineoplastic agents’.
Pixuvri pripada farmakoterapijskoj skupini lijekova poznatoj i pod nazivom “antineoplastički lijekovi”.
Pixuvri caused maternal and foetal toxicity in rats and rabbits, even at a dose as low as 1.8 mg/kg given on days 9-11 of pregnancy, higher doses resulting in abortions and total embryo resorption.
Pixuvri je pokazao toksičnost u majke i fetusa u miševa i kunića, čak i u vrlo niskim dozama od 1,8 mg/kg, primijenjenim 9.-11. dan trudnoće.
Pixuvri does not contain anything to prevent the growth of bacteria and it is, therefore, recommended that it be used immediately after reconstitution.
Pixuvri ne sadrži sredstva za sprječavanje rasta bakterija i stoga se preporučuje primijeniti ga odmah nakon pripreme.
Pixuvri Dose (mg/m2)
Pixuvri doza (mg/m2)
Pixuvri has a large volume of distribution of 25.8 l and is approximately 50% bound to plasma proteins.
Pixuvri ima veliki volumen distribucije od 25,8 l a oko 50% se veže za proteine plazme.
Pixuvri has been shown to cause phototoxic effects on 3T3 cells in vitro.
Pokazalo se da Pixuvri izaziva fototoksički efekt na 3T3 stanicama in vitro.
Pixuvri is a powder for concentrate for solution for infusion.
Pixuvri je prašak za koncentrat za otopinu za infuziju.
Pixuvri is an anticancer medicinal product that is harmful to cells; caution should be exercised in handling.
Pixuvri je protutumorski lijek koji može oštetiti stanice; potreban je oprez prilikom rukovanja.
Pixuvri is given on days 1, 8, and 15 of each 28-day cycle for up to 6 cycles.
Pixuvri se daje 1., 8., i 15. dana svakog 28-dnevnog ciklusa, do ukupno 6 ciklusa.
Pixuvri is intended for administration as a slow intravenous infusion using an in-line filter (over a minimum of 60 minutes) only after reconstitution with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection and after further dilution with sodium chloride 9 mg/ml (0.9%) solution for injection to a final volume of 250 ml.
Pixuvri je namijenjen za primjenu u obliku spore intravenske infuzije (kroz najmanje 60 minuta) uz korištenje infuzijskog filtra, ali tek nakon što je prethodno rekonstituiran dodavanjem 5 ml 0,9 %-tne otopine natrijeva klorida (fiziološkom otopinom) te naknadno dodatno razrijeđen 0,9 %-tnom otopinom natrijevog klorida (fiziološkom otopinom) do konačnog volumena od 250 ml.
Pixuvri is not recommended for use in patients with severe excretory hepatic impairment, (see section 4.3).
Pixuvri se ne preporučuje primjenjivati u bolesnika s teškim oštećenjem ekskrecijske funkcije jetre (vidjeti dio 46).